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Approaches exploiting trait distribution extremes may be used to identify loci associated with common traits, but it is unknown 
whether these loci are generalizable to the broader population. In a genome-wide search for loci associated with the upper versus 
the lower 5th percentiles of body mass index, height and waist-to-hip ratio, as well as clinical classes of obesity, including up to 
263,407 individuals of European ancestry, we identified 4 new loci (IGFBP4, H6PD, RSRC1 and PPP2R2A) influencing height 
detected in the distribution tails and 7 new loci (HNF4G, RPTOR, GNAT2, MRPS33P4, ADCY9, HS6ST3 and ZZZ3) for clinical 
classes of obesity. Further, we find a large overlap in genetic structure and the distribution of variants between traits based on 
extremes and the general population and little etiological heterogeneity between obesity subgroups.
Although it is possible that other genetic or environmental factors mod-
ify the manifestations of these variants, producing an extreme phenotype 
only in selected individuals, it is also conceivable that the trait extremes 
are, at least in part, etiologically distinct and different from those acting 
in the general population. Within the extremes of the trait distribution, 
there may be etiologically discrete subgroups or enrichment for less 
common causal variants19. Although analyzing the full distribution is 
generally more powerful, in cases where there is heterogeneity, analyzing 
extremes by case-control design may offer superior power29.
The extremes for anthropometric traits, particularly BMI, have 
been defined in numerous ways, including using the tails of the full 
population distribution (for example, >95th or >97th percentile) 
and absolute cutoffs (for example, ≥40 kg/m2) based on clinical or 
standard references, and some studies have used a combination of 
definitions for their discovery and replication analyses. The common 
denominator for studies addressing trait extremes (herein used as a 
more generic term) is that they dichotomize the trait distribution and 
analyzed data using a case-control design. Studies suggest that the 
percentile cutoff choice and ascertainment strategy used may affect 
the observed risk and subsequent power30,31; however, the conse-
quences of the definitions of trait extremes on the discovery and char-
acterization of loci for complex traits have not been systematically 
evaluated. In the present study, we have used the terms ‘distribution 
tails’ to describe analyses comparing the upper and lower 5th percen-
tiles of the trait distributions; ‘clinical classes of obesity’ to describe 
analyses where controls were subjects with BMI < 25 kg/m2 and cases 
were defined as having BMI ≥ 25 kg/m2 for the overweight class, 
BMI ≥ 30 kg/m2 for obesity class I, BMI ≥ 35 kg/m2 for obesity 
class II and BMI ≥ 40 kg/m2 for obesity class III (ref. 32); and 
‘extremely obese’ to describe studies using different sampling 
designs for selecting their extremely obese cases and controls.
The overall aim of the present study was to use and compare dif-
ferent distribution cutoffs for the identification of genetic loci for 
Genome-wide meta-analysis identifies 11 new loci  
for anthropometric traits and provides insights into 
genetic architecture
Twin studies have established a strong heritable component to body 
mass index (BMI; h2 of ~40–70%)1,2 and height (h2 of ~70–90%)3. 
Previous meta-analyses of genome-wide association studies (GWAS) 
have identified 36 genetic loci associated with BMI4–6, 14 loci associ-
ated with waist-to-hip ratio adjusted for BMI (WHR), reflecting fat 
distribution7,8, and 180 loci associated with height9 and contributed 
to our understanding of the genetic architecture of complex traits. 
However, established loci for complex traits only account for a small 
proportion of trait heritability, as discussed recently10,11. Some postu-
lated explanations for this include undiscovered low-frequency vari-
ants with larger effects, imperfect tagging of causal variants, epistasis, 
gene-environment interaction and phenotype heterogeneity. This has 
led to increasing interest in approaches exploiting extremes of the 
trait distribution where there may be less locus heterogeneity, greater 
genetic contribution and enrichment for highly penetrant variants. 
The use of population extremes has also been proposed to improve 
cost-efficiency, as effect sizes may be larger, fewer subjects may be 
needed for genotyping and a smaller proportion of the variance may 
be attributable to environmental factors. Indeed, several previous stud-
ies have used population extreme designs to discover loci for various 
complex traits, such as obesity and lipid fractions, using microarray 
genotyping12–16 or sequencing methods17–20. However, the few previ-
ous studies that have systematically addressed differences between the 
genetic architecture of the overall distribution with that of distribution 
extremes for complex traits have been small21–23, and, hence, it remains 
largely unknown whether genetic loci identified as associated with the 
extremes of a trait can be extended to the general population.
Studies of extremely obese individuals have reported 13 loci at or 
near genome-wide significance (P < 5 × 10−7)14–16,22–26, but not all have 
shown evidence of association with BMI in the general population4,27. 
For example, variants in PCSK1 (rs6232) and PTER have been convinc-
ingly associated with severe obesity14,25 but have at best shown nomi-
nal evidence of association with BMI in large-scale meta-analyses4,28. 
A full list of authors and affiliations appears at the end of the paper.
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anthropometric traits. The two specific aims were (i) to systemati-
cally compare findings using these cutoffs with those from the full 
population distribution, as well as with those from studies using a 
different ascertainment strategy, and (ii) to draw inferences about 
the value of these different approaches for sampling within a popula-
tion-based study. Our focus was primarily on BMI, which is a major 
risk factor for multiple chronic diseases and of important public 
health relevance33, but we also examined height and WHR adjusted 
for BMI (as a measure of body fat distribution) to determine whether 
our findings could be generalized to other traits. To address these 
aims, we performed a genome-wide search for genetic determinants 
of the distribution tails (defined as the upper versus lower 5th per-
centiles of the trait distribution) of BMI, height and WHR and, for 
comparison, of clinical classes of obesity drawn from populations 
within the Genetic Investigation of ANthropometric Traits (GIANT) 
Consortium. Association analyses were conducted in a study base (or 
sampling frame) of up to 168,267 individuals with follow-up of the 
273 most significantly associated loci in a study base of up to 109,703 
additional individuals. Further, systematic comparisons were con-
ducted to assess differences in genetic inheritance and the distribu-
tion of risk variants between the population extremes and the general 
population for these anthropometric traits.
RESULTS
To first evaluate the contribution of common SNPs to the anthropo-
metric trait distribution tails and clinical classes of obesity and discover 
new loci, we conducted meta-analyses of GWAS of six obesity-related 
traits (distribution tails of BMI and WHR, overweight class and 
obesity classes I–III), as well as the distribution tails of height, using 
results for ~2.8 million genotyped or imputed SNPs. Stage 1 analy-
ses included 51 studies with study bases of 158,864 (BMI), 168,267 
(height) and 100,605 (WHR) individuals of European ancestry 
(see Supplementary Table 1 for the numbers of cases and controls per 
phenotype and Supplementary Tables 2–5 for study characteristics). 
We observed an enrichment of SNPs with small association P values 
compared to the null distribution for all seven traits (quantile-quantile 
plots; Supplementary Figs. 1 and 2). The excess was diminished after 
the exclusion of loci previously established for the overall distributions 
or population extremes of these traits, but some enrichment remained, 
especially for the distribution tails of height and, to a lesser extent, 
for the overweight class and obesity classes I and II. In total, 69 loci 
(defined as separated by at least 1 Mb) were associated at P < 5 × 10−8 
with at least 1 trait (Supplementary Figs. 3 and 4).
To identify and validate loci for these traits, SNPs for which asso-
ciations reached P < 5 × 10−6 in the stage 1 analyses were taken 
forward for follow-up (stage 2) in 12 studies with in silico GWAS 
data and 24 studies with Metabochip data with study bases of 
109,703 (BMI), 107,740 (height) and 75,220 (WHR) individuals 
(Supplementary Tables 1–5).
BMI-related traits
Seventeen SNPs were taken forward to stage 2 in up to 4,900 
and 4,891 individuals from the upper and lower distribution tails 
of BMI, respectively. Ten SNPs reached genome-wide significance 
(P < 5 × 10−8) in the joint meta-analysis of stage 1 and stage 2, but 
all had been previously identified as loci associated with BMI in the 
general population4. A total of 118 SNPs were included in stage 2 
for clinical classes of obesity, which included up to 1,162 cases and 
22,307 controls for obesity class III and 65,332 cases and 39,294 
controls for the overweight class. Of the 62 SNPs that showed asso-
ciation P < 5 × 10−8 in the joint meta-analyses for at least 1 obesity 
class (Supplementary Table 6), 7 were new, explaining an additional 
0.09% of the variability in BMI (Supplementary Table 7). These 
included one locus for the overweight class (RPTOR), three loci 
for obesity class I (GNAT2, MRPS33P4 and ADCY9), two loci for 
obesity class II (HS6ST3 and ZZZ3) and one locus associated with 
both the overweight class and obesity class I (HNF4G) (Table 1 and 
Supplementary Figs. 5–7). Although these loci were identified for 
specific clinical classes of obesity, all newly associated loci showed 
consistent effect direction across the distribution tails of BMI and 
the other classes of obesity, and most P values were significant 
(P < 0.007, Bonferroni corrected for seven SNPs), except for those 
for obesity class III and the distribution tails of BMI (presumably 
owing to lower statistical power for these traits; Table 2).
Of the new obesity loci, at least four are located near genes of high 
biological relevance. In particular, rs7503807 for the overweight class 
is located within the RPTOR gene (encoding regulatory-associated 
protein of the MTOR, complex 1), which regulates cell growth in 
response to nutrient and insulin levels34, and within 500 kb of the 
BAIAP2 gene (encoding BAI1-associated protein 2), a brain-specific 
angiogenesis inhibitor (BAI1)-binding protein that regulates insulin 
uptake in the central nervous system. The rs4735692 SNP associ-
ated with the overweight class and obesity class I is located down-
stream of the HNF4G gene (encoding hepatocyte nuclear factor 4γ). 
Mutations in HNF4A, a closely related gene encoding a factor that 
forms a heterodimer with HNF4G to activate gene transcription35, 
cause maturity-onset diabetes of the young type 1 (ref. 36), and a 
common variant near HNF4A was found to be associated with type 2 
diabetes (T2D) in east Asians37. The rs2531995 SNP associated 
with obesity class I is located within ADCY9 (encoding adenylate 
cyclase 9), which catalyzes the formation of cyclic AMP from ATP. 
This SNP was found to be associated with ADCY9 expression in sev-
eral tissue types (Supplementary Table 8). Loci near other adenylate 
cyclase genes have been associated with several T2D-related traits, 
such as glucose homeostasis and susceptibility to T2D (ADCY5)38,39. 
The rs17024258 SNP associated with obesity class II is located 207 kb 
away from the lipid-related gene SORT1 (encoding sortilin), which is 
expressed in multiple cell types and has been reported to be involved 
in insulin responsiveness in adipose cells40. Lower amounts of sortilin 
have been observed in the adipose tissues of morbidly obese humans 
and mice and in the skeletal muscle of obese mice41. A more compre-
hensive summary of the biological relevance of the genes nearest to all 
newly associated loci is given in the Supplementary Note.
Distribution tails of height
A total of 134 SNPs from stage 1 were taken forward to stage 2 in up 
to 4,872 and 4,831 individuals from the upper and lower distribu-
tion tails of height, respectively. Of the 95 SNPs that reached asso-
ciation P < 5 × 10−8 in the joint meta-analysis of stage 1 and stage 2 
(Supplementary Table 6), 4 new loci (IGFBP4, H6PD, RSRC1 and 
PPP2R2A) were identified for the distribution tails of height (Table 1 
and Supplementary Fig. 8). The contribution of the four new loci to 
overall height variability was ≤0.02% (Supplementary Table 7).
Two of the new loci are located near genes that seem particularly 
relevant to height. rs584438 is located approximately 500 bp upstream 
of IGFBP4, which codes for insulin-like growth factor–binding pro-
tein 4 (IGFBP4), and is in linkage disequilibrium (LD, r2 = 0.87) 
with another SNP (rs598892) that results in a synonymous amino-
acid change in IGFBP4. IGFBP4 binds to IGF1 and IGF2 (ref. 42), 
which have an important role in childhood growth. In blood, this 
same SNP showed a significant association with the expression of 
TNS4 (Supplementary Table 8), which encodes a factor that interacts 
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with β-catenin43, a critical component of the canonical Wnt pathway 
related to bone formation44. The height-associated SNP rs2362965 
lies 285 kb away from SHOX2, a homolog to the X-linked, pseudo-
autosomal SHOX (short stature homeobox) gene family, which has a 
major role in skeletal limb development.
Distribution tails of WHR
Ten SNPs were taken forward to stage 2 in 3,351 and 3,352 individu-
als from the upper and lower distribution tails of WHR, respectively. 
The four SNPs that reached genome-wide significance (P < 5 × 10−8; 
Supplementary Table 6) have previously been identified as WHR-
associated loci in the general population7.
Effects of new loci in the full distribution and previously 
identified loci in distribution tails and obesity classes
We assessed the impact of our newly associated loci on the full distri-
bution of these anthropometric traits using data from studies included 
in stage 1 and stage 2. In the full distribution, evidence of association 
(P < 0.005, Bonferroni corrected for 11 SNPs) with consistent effect 
direction was observed with BMI for all new obesity-related trait loci 
and with height for all new loci identified for the distribution tails of 
height (Table 2). None of the loci were associated with WHR, sug-
gesting that these obesity loci are primarily associated with overall 
adiposity rather than with fat distribution.
In the GIANT Consortium, we previously identified 32 loci asso-
ciated with BMI4. There is considerable overlap of samples with 
the current study, so it is not unexpected that we observed that 
the effects of all established BMI loci were directionally consistent 
between the previous study of overall BMI and the present study of 
obesity-related traits (Supplementary Table 9). Twenty-seven of 
32 SNPs were significantly associated with the distribution tails of 
BMI (P < 0.0016, Bonferroni corrected). Although only half of the 
SNPs were significantly associated with obesity class III, presumably 
owing to smaller sample size and reduced power, the majority of SNPs 
were significantly associated with obesity class II, and all were associ-
ated with obesity class I and the overweight class.
Effects of our new loci in other studies of extreme obesity
Both empirical16 and theoretical29 work has shown that genetic archi-
tecture may differ the more extreme the selection (the further out in the 
distribution), suggesting that the ascertainment strategy may affect the 
observed results31. To evaluate the impact of the ascertainment strategy, 
we also performed analyses of all SNPs we found to be associated with 
BMI-related traits in five studies that applied other ascertainment strat-
egies to define the extremely obese class (Supplementary Tables 2–5, 
bottom; ncases = 6,848, ncontrols = 7,023). Four studies recruited partici-
pants from specialized clinics or hospitals on the basis of absolute or 
percentile-derived cutoffs, and one study used liability-based (women) and 
standard-based (men) percentile cutoffs. We performed a meta-analysis 
of these five studies and observed directionally consistent associations 
for all BMI-associated SNPs between studies (Supplementary Table 10). 
The effect sizes in these extreme obesity studies were similar to those 
observed for the distribution tails of BMI in our analysis (heterogeneity 
P value (Phet) > 0.007 for all SNPs, Bonferroni corrected). Four out 
of seven new obesity-related loci showed significance at P < 0.007 
(Bonferroni corrected) in these studies of extremely obese individuals.
Effects of known extreme obesity loci in our study
Previous studies of extreme childhood and/or adult obesity using 
different ascertainment strategies have reported genome-wide sig-
nificant or near genome-wide significant associations (P < 5 × 10−7) ta
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with FTO, MC4R, TMEM18, FAIM2, TNKS, HOXB5, OLFM4, NPC1, 
MAF, PTER, SDCCAG8, PCSK1 (rs6235 and rs6232) and KCNMA1 
(refs. 14–16,22–26). With the exception of PCSK1 (rs6232) for the 
distribution tails of BMI and MAF for the distribution tails of BMI 
and obesity class II, all associations showed consistent directions of 
effect across the BMI-related outcomes (Supplementary Table 11). Of 
the 13 loci, replication at a significance level of P < 0.004 (Bonferroni 
corrected) was observed for 4 SNPs (FTO, MC4R, TMEM18 and 
FAIM2) for the distribution tails of BMI and all clinical classes of 
obesity. Two loci, MAF and KCNMA1, which have thus far only 
been reported for extreme obesity, were not significantly associated 
with any of our traits at either a Bonferroni-corrected or nominal 
significance threshold (P < 0.05).
Empirical power comparison of the population extremes and 
the full distribution
If the trait extremes have different genetic inheritance or are etiologi-
cally more homogenous than the full distribution, analyzing extremes 
or tails of the distribution by case-control design may offer superior 
power. To test this empirically, we conducted meta-analyses of the full 
distributions of BMI and height with all studies included in stage 1 
and stage 2. Only two loci (IGFBP4 and H6PD) out of the four new 
loci for the distribution tails of height reached genome-wide signifi-
cance (P < 5 × 10−8) using the full height distribution (Table 2). Four 
loci (GNAT2, ZZZ3, HNF4G and RPTOR) out of the seven new loci 
identified for the clinical classes of obesity achieved genome-wide 
significance for the full BMI distribution. The remaining loci had 
P values of <5 × 10−5 in the full distribution and, thus, would likely 
have been detected with a larger sample size.
Genetic architecture in the distribution tails and full distribution
To investigate differences in genetic architecture between the distribu-
tion tails and the full distributions, we estimated whether the observed 
genetic effects in the distribution tails of BMI, height and WHR were 
different from what would be expected based on the full distributions 
of the corresponding traits. To do this, we first estimated the expected 
effect for each SNP in the distribution tails on the basis of the full 
distribution in each study and then carried out meta-analysis of the 
expected associations across studies. The quantile-quantile plots of 
P values testing differences between the observed and expected effects 
(Fig. 1 and Supplementary Fig. 9) did not show any enrichment, 
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Figure 1 Quantile-quantile plot of the −log10 P values for the difference 
between the observed association for the distribution tails of BMI and the 
expected association based on the overall BMI distribution.ta
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indicating that the effect sizes observed in distribution tails and those 
expected based on the overall distribution were similar. Further, com-
parable results were observed for the 32 SNPs previously associated 
with BMI in Speliotes et al.4, as well as for previously published and 
new loci for extreme obesity (Supplementary Table 12).
To further compare genetic inheritance in the distribution tails 
with that in the full distribution, we used a polygenic approach45. 
The meta-analysis results of the distribution tails and full distribution 
were used to create two polygenetic scores (by summing the number 
of risk-associated alleles at each SNP) in six studies (Supplementary 
Table 13). We found that the polygenic score based on the full BMI 
distribution consistently explained more of the variance than the 
score based on the distribution tails (for example, 15.3% versus 6.4% 
at P < 0.05) (Fig. 2 and Supplementary Table 14). Similar results 
were observed for height and WHR (Supplementary Fig. 10). On 
liability scale, the variance explained by the two polygenic scores was 
similar for different BMI-related outcomes (Supplementary Fig. 11) 
and different percentile cutoffs used to define the distribution tails 
(data not shown), suggesting that the fraction of the overall variance 
explained by SNPs is not influenced by outcome categorization but 
by the ability to accurately rank and estimate the β coefficients of 
the association, which is better achieved by using the entire study 
population instead of the distribution tails. Our results also indicate 
that genetic determinants for the distribution tails are similar to those 
for the full distribution and that common variant loci contribute to 
extreme phenotypes. However, it should be noted that our analyses 
of the upper and lower 5th percentiles of the distribution (tails) does 
not necessarily extend to more extreme cutoffs, such as the top and 
bottom 1st percentiles.
Allelic heterogeneity at new and previously identified loci
To explore enrichment for allelic heterogeneity in the distribu-
tion tails and clinical classes of obesity, we performed conditional 
analyses using a recently described method46. In these analyses, we 
found secondary signals that reached genome-wide significance 
(P < 5 × 10−8) at 17 loci, including 1 locus for the distribution 
tails of BMI (FTO), 13 loci for the distribution tails of height 
(PTCH1 (2 signals), GHSR, EDEM2, C6orf106, CRADD, EFEMP1, 
HHIP, FBXW11, NPR3, LINC00471 (also known as C2orf52), 
BCKDHB and EFR3B), 1 locus for the distribution tails of WHR 
(RSPO3), 2 loci for the overweight class (MC4R and FANCL) and 
1 locus for obesity class I (FANCL) (Supplementary Table 15). 
Whereas the secondary signals for the distribution tails of BMI 
(FTO) and WHR (RSPO3) and the overweight class and obesity class I 
(FANCL) have not been established previously, all 13 height-related 
loci identified here, as well as the MC4R locus, have previously been 
shown to have allelic heterogeneity in the general population7,9, 
suggesting that there is no enrichment in the distribution tails for 
secondary signals (Supplementary Figs. 12–14).
We also looked for evidence of enrichment of unobserved low-
frequency variants by conducting haplotype analyses within known 
and new loci, as haplotypes constructed from common SNPs may 
tag low-frequency variants that are enriched in the tails of the trait 
distributions but are rarer in the general population. Using geno-
type data from the largest studies, three signals of association were 
observed for the distribution tails of height that exceeded conserva-
tive prior odds of association of 1 in 30,000: ID4 (Bayes factor of 
118,839), LIN28B (Bayes factor of 105,478) and DLEU7 (Bayes factor 
of 66,599) (Supplementary Table 16). However, for all three loci, 
association signals were characterized by two clusters of haplotypes 
(both common and rare) and were not consistent with enrichment of 
unobserved low-frequency causal variants in the distribution tails.
DISCUSSION
In our meta-analysis of GWAS of up to 263,407 individuals of 
European ancestry, we identified 165 loci associated with distribu-
tion tails (the upper versus lower 5th percentiles) of BMI, height and 
WHR and/or clinical classes of obesity. Eleven of these loci have not 
previously been associated with anthropometric traits. Several of the 
new loci were located near strong biological candidate genes, such as 
IGFBP4 and SHOX2 for the distribution tails of height and HNF4G 
and ADCY9 for the overweight class and/or obesity class I, suggest-
ing future areas of research. Although by using different distribution 
cutoffs we discovered additional loci that would not have been identi-
fied as genome-wide significant using the full distribution of the same 
study samples, there is no evidence to suggest that the clinical classes 
of obesity are etiologically distinct, and the majority of evidence indi-
cates that the population extremes share many of the same loci with 
the general population.
To assess the impact of different distribution cutoffs on genetic 
variants associated with the population extremes, we chose to evalu-
ate the 5% tails of trait distribution and clinical classes of obesity, 
specifically obesity classes II and III. Although others have ascer-
tained population extremes differently, all variants associated with 
obesity-related traits in our meta-analysis were found to have direc-
tionally consistent results in five independent studies of extremely 
Figure 2 Variance in extreme obesity explained 
by common genetic variants. The phenotypic 
variance explained is higher when SNPs with 
lower degrees of significance are included  
in the polygenetic prediction model. The  
y axis represents the proportion of variance 
explained (Nagelkerke R2) for extreme obesity 
in six studies not included in the discovery 
meta-analysis. The thicker lines represent the 
weighted average; 95% confidence intervals 
are reported as double-headed arrows. (a) The 
prediction model was based on the results from 
the stage 1 meta-analysis of the distribution 
tails of BMI. (b) The prediction model was 
based on BMI from the full distribution 
(modified version of the previous GIANT meta-
analysis by Speliotes et al.4). The Essen Obesity 
Study was not adjusted by age.
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obese samples. Of the 13 loci previously identified as associated with 
extreme obesity14–16,22–26, nearly all (except PCSK1 (rs6232) and 
MAF) showed a consistent direction of effect in the distribution tails 
of BMI. Only two loci (MAF and KCNMA1), originally identified for 
early-onset and morbid adult obesity14,26, did not replicate for any 
of our BMI-related outcomes. Although it is possible that we had 
insufficient power if there was a substantial winner’s curse present in 
the initial publications, it is also conceivable that these susceptibility 
loci are population specific, only contribute to risk at younger ages47, 
represent false positive findings or tag rare causal variants that are 
difficult to detect in population-based samples.
Because our study was based on GWAS data, we were not well 
suited to address the role of rare variants in extreme traits. Although 
haplotype-based analyses identified strong associations of haplotypes 
in three genes with the distribution tails of height, which could sug-
gest that they are tagged by rare variants, such putative variants could 
not be established using our approach. The suggestion that rare vari-
ants could be more important in the distribution extremes of complex 
traits needs to be addressed using other study designs, such as rese-
quencing projects or using the new Exome Chip microarrays that are 
currently being analyzed in many large study samples.
Our systematic comparisons between distribution extremes and 
the full distribution yielded several important insights that also may 
be informative for other complex traits. When comparing observed 
genetic effects in distribution tails with the expected effects extrapo-
lated from the overall distributions of the corresponding traits, we 
did not observe any systematic differences. Further, we showed that 
the polygenic score based on the full distribution explained a larger 
proportion of variance than the score based on the distribution tails. 
Taken together with the finding that half of our new loci were associ-
ated at a genome-wide significant level in the overall distribution, 
this implies that there is limited etiological heterogeneity in these 
anthropometric traits. Our analysis shows that, whereas some com-
mon variants can have larger effects in the distribution extremes, 
these effects as a whole are not larger than expected based on their 
effects in the overall distribution. Further, whereas rare variants spe-
cific to the distribution extremes may still exist, the extremes share 
most of the common loci with the overall distribution.
Conclusions that can be drawn from these observations are that, 
when access is available to data for the full distribution, case-control 
analyses using population extremes can be useful to find additional loci. 
Although analyzing the full distribution is generally more powerful, 
small amounts of heterogeneity in the distribution may allow for the 
identification of additional loci by analyzing the data using different 
cutoffs, such as the distribution tails. Further, as in most cases when 
resources are limited, our results indicate that a strategy with the selec-
tion of individuals from the population extremes for genetic analyses 
could be a cost-effective approach and will likely yield loci that are rel-
evant and can largely be extended to the general population. Compatible 
with the findings from recent, smaller studies21–23, our results show that 
this theoretically appealing approach also holds empirically.
In conclusion, in our large GWAS meta-analysis including up 
to 263,407 individuals, we identified 4 new loci influencing height 
detected at the distribution tails, as well as 7 new loci for clinical 
classes of obesity. Consistent with theoretical predictions and previous 
smaller studies, our results show that there is a large overlap in terms 
of genetic structure and the distribution of variants between traits 
based on different distribution cutoffs with those from population-
level studies, but additional insight may still be gained from evaluat-
ing the population extremes. Our results are informative for designing 
future genetic studies of obesity as well as other complex traits.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METHODS
Study design. We conducted a two-stage study for the distribution tails of 
three anthropometric traits (BMI, WHR adjusted for BMI and height) and 
four clinical classes of obesity (overweight class and obesity classes I, II and 
III), followed by a combined analysis of the two stages. Stage 1 consisted of 
a meta-analysis of GWAS using data from a study base (or sampling frame) 
of up to 168,267 adult individuals of European ancestry from 51 studies 
participating in the GIANT Consortium (Supplementary Tables 1–5). In 
stage 2, 273 SNPs with P value < 5 × 10−6 were followed up in up to 109,703 
additional individuals of European descent, who included 67,243 individuals 
from 24 studies with data from the Metabochip (a custom-designed array of 
~200,000 SNPs with previous evidence of suggestive association with meta-
bolic traits) and 42,460 individuals from 12 studies with in silico replication 
GWAS data (Supplementary Tables 1–5). This gave us a study base of up to 
276,007 individuals of European descent for the joint meta-analysis of stage 
1 and stage 2. Full details of the discovery and replication stages, analysis of 
data and meta-analyses are given in the Supplementary Note. All studies 
were approved by local research ethics committees, and all participants gave 
informed consent.
Phenotype definitions. The distribution tails of the three anthropometric 
traits (BMI, WHR adjusted for BMI and height) were defined as the upper 
5th percentile (cases) and lower 5th percentile (controls) of the distribution 
stratified by sex and disease status after controlling for the following covariates: 
age, age2 and principal components for BMI; age and principal components for 
height; and age, age2, BMI and principal components for WHR. For the clini-
cal obesity classes, cases were defined by BMI ≥ 25 kg/m2 for the overweight 
class, BMI ≥ 30 kg/m2 for obesity class I, BMI ≥ 35 kg/m2 for obesity class II 
and BMI ≥ 40 kg/m2 for obesity class III. Controls were subjects with BMI 
< 25 kg/m2. A minimum of 30 cases and 30 controls for each study-specific 
stratum was required.
Association analyses and meta-analyses. Each study conducted single-marker 
association analyses assuming an additive genetic model taking genotype impu-
tation uncertainty into account. Analyses were stratified by sex (except for stud-
ies with related individuals, where analyses accounted for family structure) and 
disease status for studies that ascertained participants on the basis of a relevant 
disease (for example, diabetes). Before carrying out meta-analysis of the data, 
the results from each study were extensively reviewed using standardized quality 
control procedures to identify potential problems, such as strand issues, discrep-
ancies between the reported standard errors and P values and allele frequency 
differences. SNPs with poor imputation quality scores or estimated minor allele 
count ≤ 20 (2 × N × minor allele frequency) in each stratum (men/women or 
pooled for family-based studies) of each study were removed from analysis. 
For discovery stage 1, each stratum- and study-specific GWAS was corrected 
for genomic control. Meta-analyses were performed for each phenotype in 
METAL48 using the fixed-effects inverse variance method based on β estimates 
and standard errors from each study. The results of the discovery meta-analysis 
were corrected by an additional genomic control step. Similar methods were 
employed for the replication and joint discovery and replication analyses.
Association testing in studies of extremely obese individuals. We tested the 
association of all SNPs reaching P < 5 × 10−8 in the joint analysis of stage 1 
and stage 2 results for the BMI-related traits in five studies of extremely obese 
individuals (Supplementary Tables 2–5). For the four case-control studies 
(French Extreme Obesity Study, Essen Case-Control GWAS, GEO and GOYA), 
a fixed-effects inverse variance method was used to perform meta-analysis of 
the results. With the four case-control studies, meta-analysis was performed 
including a fifth study (Essen Obesity Trio GWAS) that has a nuclear structure, 
using a weighted z-score method that takes into account the direction but not 
the magnitude of the association.
Systematic comparison of the genetic structure between distribution tails 
and the overall distribution. For these analyses, we included all GWAS that 
provided genome-wide results for both the full distribution and the distribu-
tion tails of BMI, height and WHR. First, we used the results for the full dis-
tribution to calculate, for each genotype, the expected number of individuals 
in the upper and lower 5% tails. We used these values to perform logistic 
regression, comparing the upper and lower tails, and obtained the expected 
β values and expected standard error.
Second, we tested the differences between the expected β values and the 
observed β values obtained from the meta-analyses of the tails of the distribu-
tions. The standard error of the each difference was estimated as sqrt((expected 
standard error)2 + (observed standard error)2 − 2 × 0.65 × (expected stand-
ard error × observed standard error)), where 0.65 is the correlation between 
the expected β values and the observed β values obtained from TWINGENE 
by bootstrapping. Finally, meta-analysis was performed on the differences 
between expected β values and observed β values using the inverse variance 
method in METAL.
Polygenic comparison of genetic determinants of the BMI distribution 
tails and overall distribution. Within each trait (BMI, height and WHR), 
we aimed to compare variance explained in the distribution tails of the trait 
by two genetic (polygenic) scores obtained from (i) the meta-analyses of the 
distribution tails of the trait and (ii) the meta-analyses of the full distribution. 
To make the scores comparable, we limited polygenic score construction to 
the studies that provided genome-wide meta-analysis results for both distribu-
tion tails and the overall distribution. After LD filtering (using r2 ≥ 0.05 and 
1 Mb of distance) and excluding SNPs present in <50% of samples, we created 
polygenic scores as the weighted sum of risk alleles using the method pro-
posed by the International Schizophrenia Consortium45. For the BMI analy-
sis, the association between the polygenic scores and the distribution tails of 
BMI was investigated in four samples of extremely obese individuals and two 
independent cohort studies using the same definition of distribution tails 
(Supplementary Table 13). Only the two independent cohorts were used for 
the height and WHR analyses. To estimate the phenotypic variance explained, 
we fit logistic or linear regression models including age, sex, study-specific 
covariates and the polygenic score as predictors and the distribution tails of 
the trait or the overall trait as outcomes in separate models. The phenotypic 
variance explained by the polygenic scores was defined as the difference in 
R2 (linear regression) or Nagelkerke R2 (logistic regression) between these 
models and a basic model including only age, sex and study-specific covari-
ates as predictors.
Secondary signals analysis. To identify potential secondary signals, we used 
the approximate conditional and joint analysis previously proposed46, which 
uses summary-level statistics and the LD structure from a reference sample 
to approximate conditional P values. The meta-analysis results for each trait 
were analyzed separately with LD correction between SNPs estimated from 
6,654 unrelated individuals from the ARIC cohort.
Haplotype-based analyses. Using data from ten of the largest studies, we 
tested the association between the distribution tails of height, BMI and WHR 
and haplotypes across each established and new locus separately for males 
and females within each study using GENEBPM49. Haplotypes were estimated 
from GWAS SNP data by means of an expectation-maximization algorithm 
and then clustered according to their allelic similarity. Within a logistic regres-
sion modeling framework, haplotypes within the same cluster were assigned 
the same allelic effect, reducing the required number of parameters. Markov-
chain Monte Carlo techniques were employed to sample over the space of 
haplotype clusters and regression model parameters. Evidence in favor of a 
haplotype association with the trait was assessed by summing log10 (Bayes 
factors) across studies.
Expression quantitative trait locus (eQTL) analyses. We examined the 
cis associations between SNPs that reached genome-wide significance 
(P < 5 × 10−8) and the expression of nearby genes in multiple tissues from 
5 studies described previously: (i) subcutaneous adipose tissue (n = 603) 
and whole blood (n = 747) from deCODE50; (ii) lymphoblastoid cell lines 
(n = 830) from a childhood asthma study51; (iii) liver (n = 707), subcutaneous 
fat (n = 870) and omental fat (n = 916) tissue from a bariatric surgery study52; 
(iv) subcutaneous abdominal (n = 52) and gluteal (n = 62) adipose tissue and 
whole blood (n = 65) from MolOBB53; and (v) cortical brain tissue (n = 193) 
from a survey study54. SNPs were tested for cis associations with transcripts 
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within 500 kb or 1 Mb, assuming an additive effect of the BMI-related allele or 
using an ANOVA test with study-specific P-value thresholds used to account 
for multiple testing. Conditional analyses were performed for all expres-
sion data, except for cortical tissue, by conditioning the trait-associated SNP 
on the most significant cis-associated SNP for the particular gene transcript 
and vice versa.
A list of SNPs identified in other GWAS near new loci is given in 
Supplementary Table 17.
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